经匹配后放化疗与手术治疗局限期小细胞肺癌预后比较

doi:10.3760/cma.j.issn.1004-4221.2019.11.005

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To compare the overall survival (OS), progression-free survival (PFS) and brain metastasis free survival (BMFS) between the chemo-radiotherapy and surgical treatment for patients with limited stage small cell lung cancer (LS-SCLC). Methods Clinical data of 69 patients diagnosed with LS-SCLC undergoing surgery in Zhejiang Cancer Hospital between 2000 and 2016 were collected. According to T,N stage, treatment duration, age, gender and whether or not prophylactic cranial irradiation (PCI), 69 patients of 503 LS-SCLC patients who underwent standard radiochemotherapy were assigned into the radiochemotherapy group by using the pair-matched case-control method. Results Among 138 patients, 69 cases were allocated into the surgery group (24 cases of stage Ⅰ, 14 cases of stage Ⅱ and 31 cases of stage Ⅲ) and 69 cases in the radiochemotherapy group (24 cases of stage Ⅰ, 14 cases of stage Ⅱ and 31 cases of stage Ⅲ). The median OS time was 37.1 months (95%CI:24.1-50.2 months) in surgery group and 45.0 months (95%CI:15.8-74.2 months) in the radiochemotherapy group. The 2-and 5-year OS rates were 60% and 45% in the surgery group, and 64% and 45% in the radiochemotherapy group (P=0.846). The median PFS time was 27.1 months (95%CI:0.00-60.3 months) in the surgery group and 36.2 months (95%CI:20.9-51.4 months) in the radiochemotherapy group. The 2-and 5-year PFS rates were 52%,and 38% in the surgery group, and 56% and 40% in the chemo-radiotherapy group (P=0.610). The 2-and 5-year BMFS rates were 81% and 76% in the surgery group, and 84% and 80% in the radiochemotherapy group (P=0.774). The 5-year OS rate (62% vs. 40%,P=0.038) and 5-year PFS rate (80% vs.40%,P=0.048) for patients with stage Ⅰ LS-SCLC in the surgery group were significantly higher than those in the radiochemotherapy group. However, the 5-year BMFS rate in patients with stage Ⅰ LS-SCLC did not significantly differ between two groups (92% vs.95%, P=0.816). The 5-year OS rate (41% vs.51%, P=0.946), 5-year PFS rate (65% vs.42%, P=0.280) and 5-year BMFS rate (75% vs.78%, P=0.720) for stage Ⅱ SCLC did not significantly differ between two groups. As for stage Ⅲ SCLC patients, the OS rate (25% vs.48%, P=0.220), 5-year PFS rate (28% vs.36%, P=0.333) and 5-year BMFS rate (76% vs. 74%, P=0.84) did not significantly differ between two groups. Conclusions Surgical treatment can bring survival benefits to patients with stage Ⅰ LS-SCLC. The survival prognosis of stage Ⅱ patients is equivalent between two groups. Patients with stage Ⅲ LS-SCLC receiving radiochemotherapy obtain better survival trend compared with those undergoing surgery. The conclusion remains to be validated by studies with larger sample size or prospective investigations.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Chen Mengyuan
	Hu Xiao
	Qi Xiaofang
	Xu Yujin
	Dong Baiqiang
	Chen Yamei
	Chen Ming

Key words： Lung neoplasm/surgery Lung neoplasm/radiochemotherapy Prognosis

Received: 07 August 2018

Fund:National Natural Science Foundation of China (81402540,81401911,81672972)|National Health and Family Planning Commission Scientific Research Fund-Zhejiang Province Medical and Health Major Science and Technology Program (Provincial Joint Construction Plan) Project (WKJ-ZJ-1701)

Corresponding Authors: Chen Ming,Email:chenming@zjcc.org.cn

Cite this article:

Chen Mengyuan,Hu Xiao,Qi Xiaofang et al. Comparison of clinical prognosis of chemo-radiotherapy and surgical treatment for patients with limited stage small cell lung cancer after matching[J]. Chinese Journal of Radiation Oncology, 2019, 28(11): 821-825.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2019.11.005 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2019/V28/I11/821

[1] Govindan R,Page N,Morgensztern D,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J]. J Clin Oncol,2006,24(28):4539-4544. DOI:10.1200/JCO.2005.04.4859.
[2] Bayman NA,Sheikh H,Kularatne B,et al. Radiotherapy for small-cell lung cancer-where are we heading?[J]. Lung Cancer,2009,63(3):307-314. DOI:10.1016/j.lungcan.2008.06.013.
[3] National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology:small cell lung cancer (version 1.2016)[M]. Washington:NCCN,2016.
[4] Gong L,Wang QI,Zhao L,et.al. Factors affecting the risk of brain metastasis in small cell lung cancer with surgery:is prophylactic cranial irradiation necessary for stage Ⅰ-Ⅲ disease?[J]. Int J Radiat Oncol Biol Phys,2013,85(1):196-200. DOI:10.1016/j.ijrobp.2012.03.038.
[5] American Cancer Society (ACS). Cancer facts & gures 2010[M]. Atlanta:ACS,2010.
[6] Tsuchiya R,Suzuki K,Ichinose Y,et al. Phase Ⅱ trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage Ⅰ-Ⅲ a small cell lung cancer:the Japan clinical oncology lung cancer study group trial (JCOG9101)[J]. J Thorac Cardiovasc Surg,2005,129(5):977-983. DOI:10.1016/j.jtcvs.2004.05.030.
[7] Shields TW,Higgins GA Jr,Matthews MJ,et al. Surgical resection in the management of small cell carcinoma of the lung[J]. J Thorac Cardiovasc Surg,1982,84(4):481-488.
[8] Chi-Fu JY,Derek Y,Paul J,et al. Role of adjuvant therapy in a population-based Cohort of patients with early-stage small-cell lung cancer[J]. J Clin Oncol,2016,34(10):1057-1064. DOI:10.1200/JCO.2015.63.8171.
[9] Bischof M,Debus J,Herfarth K,et al. Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy[J]. Strahlenther Onkol,2007,183(12):679-684. DOI:10.1007/s00066-007-1740-z.
[10] Brock MV,Hooker CM,Syphard JE,et al. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy:its time has come[J]. J Thorac Cardiovasc Surg,2005,129(1):64-72. DOI:10.1016/j.jtcvs.2004.08.022.
[11] Shepherd FA,Ginsberg RJ,Feld R,et al. Surgical treatment for limited small-cell lung cancer[J]. J Thorac Cardiovasc Surg,1991,101(3):385-393.
[12] Fox W,Scadding JG. Medical research council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up[J]. Lancet,1973,2(1):63-65.
[13] Lad T,Piantadosi S,Thomas P,et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy[J]. Chest,1994,106(6):320S-323S.
[14] Eric L,Elizabeth B,Yoon KY,et al. The role of surgery in the treatment of limited disease small cell lung cancer time to reevaluate[J]. J Thorac Oncol,2008,3(11):1267-1271. DOI:10.1097/JTO.0b013e318189a860.
[15] Masayoshi I,Shinichiro M,Tsutomu Y,et al. Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System[J]. Ann Thorac Surg.2000,70(5):1615-1619.
[16] Andrzej B,Krzysztof K,Hanna KM,et al. A retrospective comparative study of surgery followed by chemotherapy vs.non-surgical management in limited-disease small cell lung cancer[J]. Eur J Cardiothorac Surg,2004,26(1):183-188. DOI:10.1016/j.ejcts.2004.04.012.
[17] Weksler B,Nason KS,Shende M,et al. Surgical resection should be considered for stage Ⅰ and Ⅱ small cell carcinoma of the lung[J]. Ann Thorac Surg,2012,94(3):889-893. DOI:10.1016/j.athoracsur.2012.01.015.
[18] Yu JB,Decker RH,Detterbeck FC,et al. Surveillance epidemiology and end results evaluation of the role of surgery for stage Ⅰ small cell lung cancer[J]. J Thorac Oncol,2010,5(2):215-219. DOI:10.1097/JTO.0b013e3181cd3208.
[19] Schreiber D,Rineer J,Weedon J,et al. Survival outcomes with the use of surgery in limited stage small cell lung cancer:should its role be re-evaluated?[J]. Cancer,2010,116(5):1350-1357. DOI:10.1002/cncr.24853.